Integumentary system disorder, non-human animal
MONDO:1011328Integumentary system disorder that occurs in non-human animals.
14 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Dog allergy vaccine shows promise in small swedish trial
Disease control Recruiting nowThis study tests a dog allergy immunotherapy called Alutard SQ Dog in 40 adults with moderate-to-severe dog allergy. Participants receive increasing doses over 13 weeks, then maintenance shots every 6-8 weeks for a year. Their symptoms and lung function are measured before and af…
Phase: PHASE4 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG alongside their u…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eye drops aim to ease painful corneal scratches in rare skin disease
Disease control Recruiting nowThis study tests an eye drop called KB803 in 16 people aged 6 months and older with dystrophic epidermolysis bullosa (DEB), a rare genetic condition causing fragile skin and recurrent corneal abrasions. Participants will receive both KB803 and a placebo in random order to see if …
Phase: PHASE3 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New gel could help heal wounds in rare skin disease
Disease control Recruiting nowThis study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could Cell-Derived vesicles heal skin wounds in epidermolysis bullosa?
Disease control Recruiting nowThis phase 1/2 trial tests a topical treatment called Ev.FV, made from cell-derived particles, to help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a genetic skin condition causing painful blisters. The study will enroll 20 participants with active wounds an…
Phase: PHASE1, PHASE2 • Sponsor: Isfahan University of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New blood test could make allergy diagnosis faster and easier
Diagnosis Recruiting nowThis study is testing a new blood test (called BÜHLMANN BAT) to see if it can help diagnose allergies to peanuts, insect venom, dust mites, hazelnut, and cat dander. About 60 people aged 1.5 years and older who are already being checked for allergies will give one extra tube of b…
Sponsor: Bühlmann Laboratories AG • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New gel could ease pain and heal wounds for kids with butterfly skin
Symptom relief Recruiting nowThis study tests a gel called TCP-25 on people with epidermolysis bullosa (EB), a condition that causes fragile skin and painful blisters. About 32 people aged 4 and older with certain types of EB will have two matching wounds treated—one with the study gel and one with a placebo…
Phase: PHASE2 • Sponsor: Xinnate AB • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Scientists probe lymph nodes to unlock cat allergy mysteries
Knowledge-focused Recruiting nowThis study looks at immune cells in the lymph nodes of 16 cat-allergic adults. Half are on long-term allergy shots (immunotherapy), half are not. Researchers will give a small cat allergen injection and then sample lymph nodes and blood to see how many analyzable cells they can c…
Phase: EARLY_PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Does a Wound-Healing gel raise cancer risk? new study aims to find out
Knowledge-focused Recruiting nowThis study follows 580 people with dystrophic or junctional epidermolysis bullosa (EB) for up to 5 years. Researchers want to see if using Filsuvez, a birch bark extract gel that helps heal blisters, changes the risk of developing skin cancer. Participants receive standard care, …
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:06 UTC